Thermo Fisher Scientific (NYSE:TMO) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Thermo Fisher Scientific to “hold” from “buy,” while analyst sentiment overall remains “Moderate Buy” with an average price target of $624.64.
• Thermo Fisher reported quarterly EPS of $6.03, beating estimates of $5.71, while revenue reached $11.99 billion, up 10.5% year over year and above consensus.
• Shares opened at $610.97, near their 52-week high of $647.00; insiders have sold approximately $44.1 million of stock over the past three months, while institutional investors own 89.23% of shares.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently commented on TMO. Citigroup cut shares of Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a report on Wednesday. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. UBS Group raised shares of Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and increased their price objective for the company from $540.00 to $730.00 in a research note on Tuesday. Scotiabank initiated coverage on shares of Thermo Fisher Scientific in a research note on Wednesday. They set an "outperform" rating on the stock. Finally, Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They set a "market perform" rating and a $520.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $624.64.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $610.97 on Friday. Thermo Fisher Scientific has a 1 year low of $435.27 and a 1 year high of $647.00. The stock has a market capitalization of $225.90 billion, a price-to-earnings ratio of 32.87, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company's 50 day simple moving average is $580.40 and its 200 day simple moving average is $518.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter last year, the business posted $4.28 EPS. The company's revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts predict that Thermo Fisher Scientific will post 25.13 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 275 shares of the firm's stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. High Note Wealth LLC lifted its holdings in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock valued at $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $28,000. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $25,000. Legacy Wealth Managment LLC ID boosted its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after purchasing an additional 22 shares in the last quarter. Finally, Birchwood Financial Partners Inc. acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.